Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
Company Research Source: Business Wire
First anti-IL5 biologic to give healthcare professionals choice of how and where their patients receive treatment LONDON--(BUSINESS WIRE)-- GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20190606005859/en/ Nucala (mepolizumab) Autoinjector (Photo: Business Wire) This approval will give healthcare professionals and people living with severe Show less Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for GSK alerts
Opt-in for
GSK alerts

from News Quantified
Opt-in for
GSK alerts

from News Quantified